Phibro Animal Health (PAHC) Cost of Revenue (2012 - 2026)

Phibro Animal Health's Cost of Revenue history runs 15 years deep, the most recent figure standing at $257.9 million for Q1 2026.

• On a quarterly basis, Cost of Revenue rose 6.01% year-over-year to $257.9 million in Q1 2026; TTM through Mar 2026 was $1.0 billion, a 24.38% increase from a year earlier, with the FY2025 full-year figure at $896.3 million, up 27.21% from the prior year.
• Cost of Revenue rose to $257.9 million in Q1 2026 per PAHC's latest filing, from $241.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $268.7 million in Q2 2025 and bottomed at $163.6 million in Q3 2023.
• The 5-year median for Cost of Revenue is $178.4 million (2023), against an average of $198.2 million.
• Across the five-year window, Cost of Revenue decreased 0.15% in 2023 and soared 44.45% in 2025, its largest moves.
• Year by year, Cost of Revenue stood at $167.3 million in 2022, then climbed by 2.43% to $171.3 million in 2023, then advanced by 21.05% to $207.4 million in 2024, then rose by 16.33% to $241.3 million in 2025, then increased by 6.89% to $257.9 million in 2026.
• Per Business Quant, the three latest PAHC Cost of Revenue figures stand at $257.9 million (Q1 2026), $241.3 million (Q4 2025), and $244.1 million (Q3 2025).